These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 30819814)

  • 1. Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Real-World Evidence Highlights Need for Worldwide Access.
    Barry PJ; Jones AM
    Ann Am Thorac Soc; 2024 Jul; 21(7):1003-1004. PubMed ID: 38949605
    [No Abstract]   [Full Text] [Related]  

  • 2. Genericisation in cost-effectiveness analysis of cystic fibrosis medicines.
    Beattie A; Moore A; Ramagopalan SV
    Lancet; 2024 Jun; 403(10444):2591-2592. PubMed ID: 38879249
    [No Abstract]   [Full Text] [Related]  

  • 3. Fractional Exhalation Nitric Oxide (FeNO) changes in cystic fibrosis patients induced by compound honey syrup: a pretest-posttest clinical trial.
    Sadr S; Tahermohammadi H; Kaveh S; Khanbabaee G; Tabatabaei SA; Choopani R; Rouzbahani AK; Fadavi N; Derikvandi S
    BMC Pulm Med; 2023 Dec; 23(1):488. PubMed ID: 38053097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide-releasing prodrug for the treatment of complex
    McDonald RA; Nagy SG; Chambers M; Broberg CA; Ahonen MJR; Schoenfisch MH
    Antimicrob Agents Chemother; 2024 Feb; 68(2):e0132723. PubMed ID: 38206003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 7. Treating Specific Variants Causing Cystic Fibrosis.
    Cutting GR
    JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment.
    Vincken S; Verbanck S; De Wachter E; Vanderhelst E
    Eur Respir J; 2019 May; 53(5):. PubMed ID: 30819814
    [No Abstract]   [Full Text] [Related]  

  • 10. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
    Mitchell RM; Jones AM; Barry PJ
    Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.